Rodolfo F. Perini - Researcher Profile

Publications

2 shown

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Brian I. Rini , Elizabeth R. Plimack , V.P. Stus +24 more

Among patients with previously untreated advanced renal-cell carcinoma, treatment with pembrolizumab plus axitinib resulted in significantly longer overall survival and progress...

2019 New England Journal of Medicine 3200 citations

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Robert J. Motzer , B. Yа. Alekseev , Sun Young Rha +35 more

Lenvatinib plus pembrolizumab was associated with significantly longer progression-free survival and overall survival than sunitinib. (Funded by Eisai and Merck Sharp and Dohme;...

2021 New England Journal of Medicine 1597 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 2
Citations: 4,797
Institution: Merck & Co., Inc., Rahway, NJ, USA (United States)

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0009-0002-4400-5260

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.